A Phase 2 interventional study of Ponesimod 10 mg and Ponesimod 20 mg in Multiple Sclerosis, sponsored by Actelion. Completed at 72 sites in 20 countries. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2025-03-30.
Sponsored by Actelion (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,192 studies in Multiple Sclerosis with a site in United States — 184 open to participants now, 259 under way, 23 of them phase 3. Multiple Sclerosis · United States.
Among the 1,192 studies in Multiple Sclerosis with a site in United States, this one is the 93rd largest by enrollment of the 879 interventional ones that give a count, is one of 42 that started in 2010, is one of 139 in phase 2, and was the 239th registered.
3,271 studies on the registry are indexed under Multiple Sclerosis; 663 are open to participants now.
Browse Multiple Sclerosis studies →184 of the 1,192 studies in Multiple Sclerosis with a site in United States are open now. Recruiting first, the newest first:
Sundance Biosciences, Inc. · Sites in United States
Ages 18–70
Genentech, Inc. · Sites in United States, Puerto Rico
Ages 18–65
The University of Texas Health Science Center, Houston · Sites in United States
Ages 18+
Washington University School of Medicine · Sites in United States
Ages 40–70
University of Texas at Austin · Sites in United States
Ages 18–80
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 431 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 212 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,192 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 142 · Phase 2 191 · Phase 3 142 · Phase 4 82
First in 1976; this study’s year is marked. 42 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 353 is above the median of 50 across 2,205 interventional studies indexed under Multiple Sclerosis.
Median enrollment 50 across the 879 interventional studies, 100 across the 302 observational. Of the 818 that completed or were terminated, 332 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
376 of 1,192 have an industry lead sponsor. The 10 most frequent:
This study is registered under Actelion, one of the names counted as Johnson & Johnson. Under that name alone:
Actelion is the lead sponsor of 143 studies on the registry; 1 is open to participants now.
Of its 28 completed or terminated interventional studies of FDA-regulated products, 25 (89%) have results posted.
Johnson & Johnson has 7 studies filed under Multiple Sclerosis — fewer than ten, so there is no comparison to draw.
78 of the studies in Multiple Sclerosis with a site in United States that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05134441Phase 3Immunic AGStudy to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis | 2026-11 |
| NCT05877963Phase 3TG Therapeutics, Inc.Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab | 2027-01-21 |
| NCT06136728Phase 3MGH Institute of Health ProfessionsDalfampridine Combined With Physical Therapy for Mobility Impairment in Multiple Sclerosis | 2027-05 |
| NCT06141473Phase 3SanofiEfficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis | 2027-05-06 |
| NCT07325292Phase 3SanofiNon-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis | 2027-07-15 |
Add all 78 to your calendar (.ics) → With an account.
Among the 1,192 studies in Multiple Sclerosis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is an extension to the study AC-058B201 and will investigate the long-term safety, tolerability and efficacy of ponesimod in patients with relapsing-remitting multiple sclerosis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ponesimod 10 mg oral use
Drug: Ponesimod 10 mg
Ponesimod 20 mg oral use
Drug: Ponesimod 20 mg
Ponesimod 40 mg oral use
Drug: Ponesimod 40 mg
Ponesimod 10 mg oral use
Ponesimod 20 mg oral use
Ponesimod 40 mg oral use
Annualized Relapse Rate (ARR) of Confirmed Relapses
ARR is defined as the number of confirmed relapses per year. A relapse is defined as the occurrence of an acute episode of one or more new symptoms, or worsening of existing symptoms of multiple sclerosis (MS), not associated with fever or infection, and lasting for at least 24 hours after a stable period of at least 30 days. A confirmed relapse is a relapse accompanied by an increase from the previous clinically stable assessment (that is, performed at least 30 days after the onset of any previous relapse) of at least 0.5 point in the Expanded Disability Status Scale (EDSS) score, or one point in the score for at least one of the Functional System (FS) scores, excluding the bowel and bladder, and mental FS. EDSS is ordinal clinical scale ranges 0 (normal neurological examination) to 10 (death due to MS).
Time frame: From ponesimod start date up to the end of Analysis Period (AP) 3. The actual time varied for each participant and could be up to 13.3 years
Time to First Confirmed Relapse
Time to first confirmed relapse was reported. A relapse is defined as the occurrence of an acute episode of one or more new symptoms, or worsening of existing symptoms of multiple sclerosis (MS), not associated with fever or infection, and lasting for at least 24 hours after a stable period of at least 30 days. A confirmed relapse is a relapse accompanied by an increase from the previous clinically stable assessment (that is, performed at least 30 days after the onset of any previous relapse) of at least 0.5 point in the Expanded Disability Status Scale (EDSS) score, or one point in the score for at least one of the Functional System (FS) scores, excluding the bowel and bladder, and mental FS. EDSS is ordinal clinical scale ranges from 0 (normal neurological examination) to 10 (death due to MS).
Time frame: From ponesimod start date up to the end of Analysis Period (AP) 3. The actual time varied for each participant and could be up to 13.3 years
Time to 24 Weeks Confirmed Disability Progression
Time to 24 weeks confirmed disability progression (accumulation) was reported. Disability progression is defined as an increase of at least 1 point in the EDSS score if baseline EDSS was between 1 and 5.0, an increase of at least 1.5 points if baseline EDSS was 0, or an increase of at least 0.5 points if the baseline EDSS was equal or greater than 5.5. A 24-week confirmed disability progression is defined as a 24-week sustained increase from baseline in the EDSS scores, that is, every EDSS score (scheduled or unscheduled, with or without relapse) within a 24-week duration after the first progression should meet the progression criteria as specified above. EDSS is ordinal clinical scale ranges from 0 (normal neurological examination) to 10 (death due to MS).
Time frame: From ponesimod baseline up to the end of Analysis Period (AP) 3. The actual time varied for each participant and could be up to 13.3 years
Number of Participants With at Least One Treatment-emergent Serious Adverse Events (SAEs)
Number of participants with at least one treatment-emergent SAEs were reported. An adverse event (AE) is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. An SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalisation; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly/birth defect; suspected transmission of any infectious agent via a medicinal product or medically important. Treatment-emergent SAEs were those SAEs that occurred at or after the initial administration of ponesimod up to 15 days (inclusive) after last administration of ponesimod as study drug.
Time frame: From ponesimod start date up to the end of study treatment + 15 Days. The actual time of observation varied for each participant and could be up to 12.97 years + 15 days
Participants who were enrolled in the core study (NCT01006265) entered this extension study. As planned, combined analysis (core plus extension study) was done for efficacy and safety (435 participants).
| Milestone | Ponesimod 10 Milligrams (mg) | Ponesimod 20 Milligrams (mg) | Ponesimod 40 Milligrams (mg) |
|---|---|---|---|
| Started | 115 | 121 | 117 |
| Completed | 71 | 80 | 76 |
| Not completed | 44 | 41 | 41 |
| Withdrew: Death | 0 | 1 | 0 |
| Withdrew: Lack of efficacy | 7 | 6 | 3 |
| Withdrew: Lost to follow-up | 2 | 5 | 4 |
| Withdrew: Physician decision | 3 | 1 | 3 |
| Withdrew: Withdrawal by subject | 30 | 27 | 26 |
| Withdrew: Adverse event | 2 | 1 | 4 |
| Withdrew: Other | 0 | 0 | 1 |
ARR is defined as the number of confirmed relapses per year. A relapse is defined as the occurrence of an acute episode of one or more new symptoms, or worsening of existing symptoms of multiple sclerosis (MS), not associated with fever or infection, and lasting for at least 24 hours after a stable period of at least 30 days. A confirmed relapse is a relapse accompanied by an increase from the previous clinically stable assessment (that is, performed at least 30 days after the onset of any previous relapse) of at least 0.5 point in the Expanded Disability Status Scale (EDSS) score, or one point in the score for at least one of the Functional System (FS) scores, excluding the bowel and bladder, and mental FS. EDSS is ordinal clinical scale ranges 0 (normal neurological examination) to 10 (death due to MS).
| Confirmed relapses per year | Ponesimod 10 Milligrams (mg) | Ponesimod 20 Milligrams (mg) | Ponesimod 40 Milligrams (mg) |
|---|---|---|---|
| Annualized Relapse Rate (ARR) of Confirmed Relapses | 0.205 (0.150 to 0.282) | 0.142 (0.102 to 0.198) | 0.150 (0.105 to 0.215) |
Time to first confirmed relapse was reported. A relapse is defined as the occurrence of an acute episode of one or more new symptoms, or worsening of existing symptoms of multiple sclerosis (MS), not associated with fever or infection, and lasting for at least 24 hours after a stable period of at least 30 days. A confirmed relapse is a relapse accompanied by an increase from the previous clinically stable assessment (that is, performed at least 30 days after the onset of any previous relapse) of at least 0.5 point in the Expanded Disability Status Scale (EDSS) score, or one point in the score for at least one of the Functional System (FS) scores, excluding the bowel and bladder, and mental FS. EDSS is ordinal clinical scale ranges from 0 (normal neurological examination) to 10 (death due to MS).
| Weeks | Ponesimod 10 Milligrams (mg) | Ponesimod 20 Milligrams (mg) | Ponesimod 40 Milligrams (mg) |
|---|---|---|---|
| Time to First Confirmed Relapse | 272.3 (164.6 to NA) | 656.7 (278.0 to NA) | 431.7 (296.3 to NA) |
Time to 24 weeks confirmed disability progression (accumulation) was reported. Disability progression is defined as an increase of at least 1 point in the EDSS score if baseline EDSS was between 1 and 5.0, an increase of at least 1.5 points if baseline EDSS was 0, or an increase of at least 0.5 points if the baseline EDSS was equal or greater than 5.5. A 24-week confirmed disability progression is defined as a 24-week sustained increase from baseline in the EDSS scores, that is, every EDSS score (scheduled or unscheduled, with or without relapse) within a 24-week duration after the first progression should meet the progression criteria as specified above. EDSS is ordinal clinical scale ranges from 0 (normal neurological examination) to 10 (death due to MS).
| Weeks | Ponesimod 10 Milligrams (mg) | Ponesimod 20 Milligrams (mg) | Ponesimod 40 Milligrams (mg) |
|---|---|---|---|
| Time to 24 Weeks Confirmed Disability Progression | NA (470.3 to NA) | NA (NA to NA) | NA (NA to NA) |
Number of participants with at least one treatment-emergent SAEs were reported. An adverse event (AE) is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. An SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalisation; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly/birth defect; suspected transmission of any infectious agent via a medicinal product or medically important. Treatment-emergent SAEs were those SAEs that occurred at or after the initial administration of ponesimod up to 15 days (inclusive) after last administration of ponesimod as study drug.
| Participants | Ponesimod 10 Milligrams (mg) | Ponesimod 20 Milligrams (mg) | Ponesimod 40 Milligrams (mg) |
|---|---|---|---|
| Number of Participants With at Least One Treatment-emergent Serious Adverse Events (SAEs) | 32 | 35 | 25 |
Collected over For Serious and Non-serious AEs: From ponesimod start date up to end of treatment + 15 days (up to 12.97 years + 15 days); For All-cause Mortality: From ponesimod start date to end of Analysis Period 3 (up to 13.3 years). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ponesimod 10 Milligrams (mg) | 0/139 (0%) | 32/139 (23%) | 121/139 (87.1%) |
| Ponesimod 20 Milligrams (mg) | 1/145 (0.7%) | 35/145 (24.1%) | 125/145 (86.2%) |
| Ponesimod 40 Milligrams (mg) | 0/151 (0%) | 25/151 (16.6%) | 140/151 (92.7%) |
| Event | Ponesimod 10 Milligrams (mg) | Ponesimod 20 Milligrams (mg) | Ponesimod 40 Milligrams (mg) |
|---|---|---|---|
| Uterine LeiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 3/139 | 2/145 | 0/151 |
| Atrioventricular Block Second DegreeCardiac disorders | 2/139 | 1/145 | 0/151 |
| VertigoEar and labyrinth disorders | 2/139 | 0/145 | 0/151 |
| Ankle FractureInjury, poisoning and procedural complications | 2/139 | 0/145 | 0/151 |
| EndometriosisReproductive system and breast disorders | 2/139 | 0/145 | 1/151 |
| Macular OedemaEye disorders | 0/139 | 2/145 | 1/151 |
| CholelithiasisHepatobiliary disorders | 1/139 | 2/145 | 0/151 |
| Road Traffic AccidentInjury, poisoning and procedural complications | 0/139 | 2/145 | 0/151 |
| Invasive Ductal Breast CarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/139 | 2/145 | 1/151 |
| Intermenstrual BleedingReproductive system and breast disorders | 0/139 | 2/145 | 0/151 |
| Event | Ponesimod 10 Milligrams (mg) | Ponesimod 20 Milligrams (mg) | Ponesimod 40 Milligrams (mg) |
|---|---|---|---|
| NasopharyngitisInfections and infestations | 46/139 | 46/145 | 45/151 |
| HeadacheNervous system disorders | 38/139 | 31/145 | 41/151 |
| Upper Respiratory Tract InfectionInfections and infestations | 27/139 | 28/145 | 39/151 |
| CoughRespiratory, thoracic and mediastinal disorders | 11/139 | 13/145 | 28/151 |
| Back PainMusculoskeletal and connective tissue disorders | 21/139 | 23/145 | 22/151 |
| BronchitisInfections and infestations | 22/139 | 22/145 | 21/151 |
| HypertensionVascular disorders | 22/139 | 19/145 | 18/151 |
| Urinary Tract InfectionInfections and infestations | 21/139 | 21/145 | 22/151 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 21/139 | 16/145 | 16/151 |
| InfluenzaInfections and infestations | 20/139 | 18/145 | 20/151 |
| Age, Categorical(Participants) | Ponesimod 10 Milligrams (mg) | Ponesimod 20 Milligrams (mg) | Ponesimod 40 Milligrams (mg) | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 115 | 121 | 117 | 353 |
| >=65 years | 0 | 0 | 0 | 0 |
| Age, Continuous(years) | Ponesimod 10 Milligrams (mg) | Ponesimod 20 Milligrams (mg) | Ponesimod 40 Milligrams (mg) | Total |
|---|---|---|---|---|
| Mean | 36.6 ± 8.67 | 36.1 ± 8.58 | 35.9 ± 8.61 | 36.2 ± 8.6 |
| Sex: Female, Male(Participants) | Ponesimod 10 Milligrams (mg) | Ponesimod 20 Milligrams (mg) | Ponesimod 40 Milligrams (mg) | Total |
|---|---|---|---|---|
| Female | 77 | 80 | 76 | 233 |
| Male | 38 | 41 | 41 | 120 |
| Ethnicity (NIH/OMB)(Participants) | Ponesimod 10 Milligrams (mg) | Ponesimod 20 Milligrams (mg) | Ponesimod 40 Milligrams (mg) | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 2 | 2 |
| Not Hispanic or Latino | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 115 | 121 | 115 | 351 |
| Race (NIH/OMB)(Participants) | Ponesimod 10 Milligrams (mg) | Ponesimod 20 Milligrams (mg) | Ponesimod 40 Milligrams (mg) | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 0 | 1 |
| Asian | 0 | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 3 | 2 | 4 | 9 |
| White | 112 | 118 | 110 | 340 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 2 | 2 |
| Region of Enrollment(Participants) | Ponesimod 10 Milligrams (mg) | Ponesimod 20 Milligrams (mg) | Ponesimod 40 Milligrams (mg) | Total |
|---|---|---|---|---|
| Austria | 4 | 2 | 2 | 8 |
| Bulgaria | 5 | 3 | 5 | 13 |
| Canada | 2 | 2 | 2 | 6 |
| Czech Republic | 12 | 17 | 14 | 43 |
| Finland | 6 | 6 | 4 | 16 |
| France | 1 | 1 | 1 | 3 |
| Germany | 1 | 1 | 2 | 4 |
| Hungary | 2 | 8 | 5 | 15 |
| Israel | 0 | 2 | 1 | 3 |
| Italy | 8 | 8 | 6 | 22 |
| Netherlands | 0 | 1 | 1 | 2 |
| Poland | 14 | 6 | 11 | 31 |
| Romania | 1 | 2 | 0 | 3 |
| Russia | 8 | 11 | 11 | 30 |
| Serbia | 16 | 13 | 11 | 40 |
| Spain | 1 | 4 | 4 | 9 |
| Sweden | 4 | 6 | 8 | 18 |
| Switzerland | 2 | 1 | 0 | 3 |
| Ukraine | 4 | 7 | 5 | 16 |
| United Kingdom | 5 | 4 | 5 | 14 |
| United States | 19 | 16 | 19 | 54 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from May 2010 to primary completion in Sep 2023, 159 months.
Results were first posted in Oct 2024, 1 year after primary completion.
Of 43 industry-sponsored phase 2 interventional studies under Multiple Sclerosis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 47. This study's 159 months is above that.
Counting every sponsor, half of 92 studies reached it within 36 months; a quarter within 19 and three quarters within 64.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ponesimod